Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile
Katherine Tarlock1, 2, Jessica A. Pollard3, 4, Todd A. Alonzo5, 6, et al.
1 Department of Hematology& Oncology, Seattle Children's Hospital, Seattle, WA, USA
2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
3 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA
4 Harvard Medical School, Boston, MA, USA
5 Children's Oncology Group, Monrovia, CA, USA
6 Division of Biostatistics, University of Southern California, Los Angeles, CA, USA
Program: Oral and Poster Abstracts Type: Oral Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, Excluding Transplantation: Induction and Post-Remission Therapy Hematology Disease Topics & Pathways: AML, Diseases, Therapies, Non-Biological, Chemotherapy, Myeloid Malignancies Saturday, December 7, 2019: 10:30 AM W304, Level 3 (Orange County Convention Center) Authors: Katherine Tarlock1, 2, Jessica...